Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy targets rare abdominal tumor before surgery

NCT ID NCT03361436

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times

Summary

This early-stage trial tests the safety and best dose of the chemotherapy drug eribulin given together with radiation before surgery for a rare cancer called retroperitoneal liposarcoma. About 15 adults with this tumor will receive the combination to see how well they tolerate it. The goal is to find a way to shrink the tumor before removal, potentially improving outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • OHSU Knight Cancer Institute

    Portland, Oregon, 97239, United States

Conditions

Explore the condition pages connected to this study.